Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A

Documenti analoghi

• Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study
  di: Behnaz Pezeshkpoor, et al.
  Pubblicazione: (2024)
• Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
  di: Davide Matino, et al.
  Pubblicazione: (2024)
• Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels
  di: Kerstin Herbst, et al.
  Pubblicazione: (2026)
• Profiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’
  di: Ann‐Cristin Berkemeier, et al.
  Pubblicazione: (2025)
• Self‐conducted sonographic monitoring of the knee in patients with haemophilia—A feasibility study
  di: Anna Christina Strauss, et al.
  Pubblicazione: (2024)